We’ve assembled the most frequently asked questions about Eversense into one place. Got a question that you can’t find the answer to? Contact us.
To reset the transmitter, follow these steps:
High Alert – 250 mg/dL
Low Alert – 65 mg/dL
High Target – 180 mg/dL
Low Target - 70 mg/dL
The Smart Transmitter sends glucose data via Bluetooth® to your mobile device running the Eversense® App.
The Eversense® CGM is compatible with Glooko.
Syncing data to Glooko is initiated via the user’s Glooko account. They will need to know their Eversense username and password to link their Eversense account via Glooko.
| Characteristics | Description |
|---|---|
| Class | II |
| Type | AC Input, 100-240Vac, 50/60Hx, 0.3-0.15A |
| DC Output | 5V DC, 1A (5.0 watts) |
| Moisture Protection (charging cradle) | IP22 (Protected from touch by fingers and objects greater than 12 millimeters. Protected from water spray or dripping water from vertical angle.) |
Removing an Eversense® CGM user from your list means you will no longer be able to remotely monitor their glucose data. To add a user back to your list, contact the Eversense® CGM user to send you a new invitation.
To add a user back to your list, contact the Eversense® CGM user to send you a new invitation.
Note: It can take up to 2 hours for the Eversense® CGM user to see that you are no longer in their Circle on their Eversense® CGM App.
Still have questions?
The Eversense team is dedicated and ready to provide the answers and support you need. Simply click the link below.
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For important safety information, see bit.ly/eversensesafety
Eversense, Eversense E3 Continuous Glucose Monitoring, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.
MKT-001692 Rev 1